Carl Zeiss Meditec Shares Plunge to Multi-Year Low

Carl Zeiss Meditec shares plunge 64% in a year, trading at a deep discount to peers after management slashed its annual forecast due to operational headwinds.

Carl Zeiss Meditec's stock has reached its lowest valuation in a decade, reflecting mounting investor concerns. The sustained selling pressure continues unabated, even at these significantly reduced price levels, following a substantial downward revision of the company's outlook by its executive team.

Valuation Gap Emerges Amid Persistent Weakness

The share price, currently trading at €23.48, is also at its 52-week low. This represents a staggering 64% decline over the past twelve months, with the stock now trading more than 42% below its 200-day moving average—a clear indicator of the severe loss of market confidence.

Despite this dramatic collapse, a notable valuation discrepancy has appeared. The stock now trades at a price-to-earnings (P/E) ratio of approximately 19, which is significantly lower than the industry average P/E of around 28. This could point to a discounted valuation, but analysts caution that this discount is only justified if the company's cash flows demonstrate stabilization in the coming years.

Operational Headwinds Trigger Guidance Cut

The driving forces behind the sell-off are concrete operational challenges. The company faced a difficult start to its current fiscal year, heavily impacted by unfavorable currency exchange effects and tepid demand. In response to these conditions, management was compelled to issue a stark warning and significantly lower its annual forecast.

While market observers generally acknowledge the firm's solid fundamental market position, they emphasize that a difficult operating environment is expected to persist throughout the entire 2026 fiscal year.

Key Dates for Investor Watch

In the near term, market attention is focused on three specific events. The company's virtual Annual General Meeting is scheduled for March 26, where a dividend proposal of €0.55 per share will be put to a vote. This will be followed by the release of second-quarter 2026 results on May 15. Investors will scrutinize these figures for any initial signs of an operational recovery. The question of when—or if—the stock will find a stable footing remains open.